Citadel Advisors’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Citadel Advisors’s Portfolio ANTH Stock Details ANTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-35,297	Closed	-$11K	–	9613
2018 Q1	$11K	Buy	+35,297	New	+$52.7K	﹤0.01%	8180
2017 Q2	–	Sell	-1,498	Closed	-$5K	–	8445
2017 Q1	$5K	Sell	1,498 -28,176	-95%	-$133K	﹤0.01%	7359
2016 Q4	$154K	Buy	29,674 +27,854	+1,530%	+$482K	﹤0.01%	6492
2016 Q3	$46K	Sell	1,820 -289	-14%	-$7.29K	﹤0.01%	6874
2016 Q2	$52K	Buy	+2,109	New	+$59.6K	﹤0.01%	6400
2016 Q1	–	Sell	-770	Closed	-$29K	–	8701
2015 Q4	$29K	Sell	770 -21,689	-97%	-$957K	﹤0.01%	7687
2015 Q3	$1.09M	Buy	22,459 +16,809	+298%	+$1.17M	﹤0.01%	3697
2015 Q2	$390K	Buy	5,650 +2,011	+55%	+$93.1K	﹤0.01%	5359
2015 Q1	$130K	Buy	3,639 +1,322	+57%	+$39.1K	﹤0.01%	6626
2014 Q4	$29K	Buy	2,317 +1,536	+197%	+$22.3K	﹤0.01%	7576
2014 Q3	$12K	Sell	781 -377	-33%	-$7.93K	﹤0.01%	7712
2014 Q2	$31K	Buy	+1,158	New	+$28.6K	﹤0.01%	7067

Other funds holding ANTH

Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Citadel Advisors's ANTH Position: Q2 2018 in Review

Citadel Advisors sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q2 2018, closing a stake of 35,297 shares — an estimated $11K sold.

Citadel Advisors first reported a position in ANTH in Q2 2014 and held it in 12 quarters. The position peaked at $1.09M in Q3 2015. 5 funds tracked by Wall St. Rank hold ANTH as of Q2 2018.

Citadel Advisors reported no remaining Anthera Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Citadel Advisors sold 35,297 Anthera Pharmaceuticals, Inc. shares in Q2 2018, an estimated $11K.
Citadel Advisors first reported a position in Anthera Pharmaceuticals, Inc. in Q2 2014 and held it in 12 quarters.
Citadel Advisors's Anthera Pharmaceuticals, Inc. position peaked at $1.09M in Q3 2015.
5 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q2 2018.

Based on Citadel Advisors's 13F filing for Q2 2018, filed 10 Aug 2018.